Summit Therapeutics

Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile in Ph II Trial
CP Wire
Summit Therapeutics
C. difficile
microbiome ridinilazole
Flag link:
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
Flag link:
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Data from trials could send these clinical-stage biotech stocks soaring or crashing
Motley Fool
clinical trials
biotech
Summit Therapeutics
DMD
Jounce Therapeutics
JTX-2011
TG Therapeutics
ublituximab
Flag link:
How the newest Duchenne biotechs are getting a boost from patient groups
How the newest Duchenne biotechs are getting a boost from patient groups
Bizjournals.com
patients
patient groups
Duchenne Muscular Dystrophy
Sarepta Therapeutics
Santhera
Catabasis
Akashi Therapeutics
Summit Therapeutics
Solid Biosciences
Flag link:
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Sarepta Wins Exclusive License, Collaboration Deal for European Rights To Summit's DMD Drug
Yahoo/Benzinga
Sarepta Therapeutics
Europe
Duchenne Muscular Dystrophy
Summit Therapeutics
ezutromid
Flag link:
Sarepta: The Competition Is At The Gate
Sarepta: The Competition Is At The Gate
Seeking Alpha
Sarepta Therapeutics
eteplirsen
Biomarin
Summit Therapeutics
PTC Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Summit develops a unique Duchenne drug for any gene mutation
Summit develops a unique Duchenne drug for any gene mutation
Bizjournals.com
Summit Therapeutics
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Flag link:
Summit pulls off a downsized IPO for its DMD drug
Summit pulls off a downsized IPO for its DMD drug
Fierce Biotech
Duchenne Muscular Dystrophy
Summit Therapeutics
SMT C1100
IPOs
Flag link: